Halozyme Therapeutics (HALO) Recovering Nicely Off of February Lows
Mid-Market Update: I talked about Halozyme Therapeutics (HALO, $11.98 up $0.16) on a technical level in today’s Pre-Market Update, but I wanted to profile the stock’s fundamental story for you this afternoon as well.